Loading
Life sciences · Journal article
Advanced Science · October 31, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
ABSTRACT Tumor‐resident intracellular bacteria (TRIB) are prevalent within triple‐negative breast cancer (TNBC). As integral components of the tumor pathological microenvironment, TRIB accelerate TNBC development by regulating cell proliferation, metabolism and immunosuppression. They also enhance the resistance of circulating tumor cells to mechanical stress through cytoskeletal rearrangement, boosting tumor metastasis and hindering clinical therapy. This work develops an advanced TRIB‐targeted therapeutic strategy to block TNBC progression by eliminating tumor cells and intracellular bacteria, remodeling tumor immunity and suppressing metastatic colonization. We fabricate cancer cell membrane‐modified narrow‐bandgap FeSe 2 nanosheets for enhanced ultrasound‐triggered reactive oxygen species production and image‐guided precise treatment. Such nanoplatforms utilize endogenous H 2 O 2 and GSH to amplify chemodynamic effects, induce severe oxidative stress and ferroptosis in tumor cells. Combined damage‐associated and pathogen‐associated molecular patterns efficiently activate dendritic cells and initiate robust antigen‐specific T‐cell immune responses. This study provides an alternative and promising strategy for the treatment of clinically metastatic breast cancer through intratumoral microbiota intervention.